Friedl-Naderer Johanna (CIK 1915598) reported 11 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-09-08). Recent activity: Sell DYN (900 shares), Sell DYN (185 shares), Sell DYN (226 shares), Sell DYN (145 shares), Sell DYN (228 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-08 | Dyne Therapeutics, Inc. (DYN) | Chief Commercial Officer | Sell | 900 | $21,915 |
| 2026-09-08 | Dyne Therapeutics, Inc. (DYN) | Chief Commercial Officer | Sell | 185 | $3,493 |
| 2026-08-17 | Dyne Therapeutics, Inc. (DYN) | Chief Commercial Officer | Sell | 226 | $5,939 |
| 2026-06-17 | Dyne Therapeutics, Inc. (DYN) | Chief Commercial Officer | Sell | 145 | $2,658 |
| 2026-05-14 | Dyne Therapeutics, Inc. (DYN) | Chief Commercial Officer | Sell | 228 | $4,186 |
| 2026-03-06 | Dyne Therapeutics, Inc. (DYN) | Chief Commercial Officer | Sell | 148 | $2,205 |
| 2026-02-17 | Dyne Therapeutics, Inc. (DYN) | Chief Commercial Officer | Buy | 60,000 | $0 |
| 2025-12-05 | Dyne Therapeutics, Inc. (DYN) | Chief Commercial Officer | Sell | 144 | $2,984 |
| 2025-09-08 | Dyne Therapeutics, Inc. (DYN) | Chief Commercial Officer | Sell | 894 | $11,863 |
| 2025-09-08 | Dyne Therapeutics, Inc. (DYN) | Chief Commercial Officer | Sell | 144 | $1,931 |
| 2025-06-06 | Dyne Therapeutics, Inc. (DYN) | Chief Commercial Officer | Sell | 146 | $1,949 |
来源：SEC Form 4 申报文件 · 截至 2026-09-08